PSK Pharma has registered Respiforb Air, a combination of budesonide and formoterol, for the treatment of bronchial asthma. The drug called Respiforb Air will be produced at the company’s own production facility, the press service of PSK Pharma reported.
The inhaler provides 120 doses and comes in two versions: with and without an indicator of the remaining quantity. The inhalation form allows a flexible approach to the choice of the active substance delivery device, since not all patients can use a powder inhaler due to individual physiological characteristics or intolerance to excipients.
In pulmonology in Russia and the world, there is a tendency to prescribe double combinations (iGCS/LABA) for bronchial asthma. Russian doctors prescribe budesonide + formoterol more often than other combinations, PSK Pharma explained. The drug effectively targets both inflammation and smooth muscle dysfunction in the respiratory tract. This combination has been approved for patients aged six and older and is gaining traction, with a reported market volume exceeding 190,000 packages in the Russian public procurement sector for aerosol formulations in 2024.
Earlier, PSK Pharma reported that they had received registration certificates for four other drugs. One is Russia’s first medicine with INN tirofiban; branded as Tirofiban PSK, it is used for the treatment of acute coronary syndromes. It is supplied as a concentrate for the preparation of an infusion solution. The Ministry of Health also registered Ambrisentan PSK, Russia’s generic version of GSK’s Volibris, for the treatment of pulmonary arterial hypertension (PAH).
The portfolio of PSK Pharma now also features sugammadex, which is used in anesthesiology and intensive care. The drug, Sudzhecta, is an analog of MSD’s Bridan. The patent for the molecule of the original drug expires in Russia in May 2025. In 2024, Sotex also received a registration certificate for Russia’s first sugammadex-based drug, which it brands as Destinil. Moreover, PSK Pharma is launching Teduglutide, marking the debut of the first domestic drug for short bowel syndrome treatment.
